The company outperformed when it last reported, so why has the CSL share price been languishing?

CSL has been stuck in the mud. What;s next?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • CSL shares have failed to go anywhere for months now 
  • That's despite what was a well-received earnings report back in February 
  • So what's next for CSL? 

The CSL Limited (ASX: CSL) share price has been a bit of a disappointing investment in 2022 thus far. As it stands today, CSL shares are currently down 9.42% year to date. That includes the rather nasty 1.05% haircut we've seen so far today, which currently puts CSL at $268.12. 

What might be even more disappointing for CSL investors though is the cool off we've seen since the ASX 200 healthcare giant reported its half-year earnings back in February. CSL dropped its numbers on 16 February. These were exceedingly well received at the time, evidenced by the CSL share price's 14% rise between 15 and 17 February.

However, investor sentiment has cooled since then. At today's share pricing, CSL is now more than 3% off of those highs reached on 17 February.

So what's possibly gone awry at CSL that has caused this seeming share price malaise? 

A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

Why can't the CSL share price get out of neutral?

Well, unfortunately, we can't say for sure. The company hasn't really given investors any major news since its earnings report, apart from a minor update to its ongoing quest to acquire the Swiss biotech company Vifor Pharma. But that doesn't seem to have had much of an impact on CSL shares then or since.

But what we do know is that one expert ASX investor is eyeing off what she sees as a bargain. Writing in the Australian Financial Review (AFR) today, Jun Bei Liu of Tribeca Investment Partners, calls CSL a quality company that investors have still chosen to sell off. She noted how the CSL share price "outperformed expectations by over 10 per cent" at its earnings, so questions why its shares have fallen since then. That's despite what she describes as an "exceptionally defensive global growth profile".

Ms Liu estimates that CSL will "deliver in excess of 20 per cent returns" this year, here's why:

As we move through the market uncertainty and geopolitical conflicts, confidence will return, and quality names will be the first to close the valuation gap.

At the current CSL share price, this ASX 200 health care share has a market capitalisation of $130.52 billion. 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

These two stocks have big upside.

Read more »

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses

Clarity Pharmaceuticals reported strong FY26 revenue growth, a wider loss, and progress towards commercialisation of its radiopharmaceutical pipeline.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend

Clinuvel Pharmaceuticals reported its tenth straight profit, rising cash reserves, and steady dividend for FY2026.

Read more »

Man and woman sitting at table with the man looking a bit puzzled at his laptop.
Healthcare Shares

Should I buy CSL shares before the end of August?

I think the company's earnings outlook is starting to look more encouraging.

Read more »

Female pharmacist smiles with a digital tablet.
Earnings Results

Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth

The company reported double-digit revenue growth.

Read more »